Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference

EXTON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
August 09, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights

EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
August 02, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights

EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
July 05, 2018 16:05 ET | Source: Fibrocell Science Inc.

Fibrocell Announces Closing of $4.0 Million Registered Direct Offering

EXTON, Pa., July 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
July 02, 2018 09:00 ET | Source: Fibrocell Science Inc.

Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market

EXTON, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 31, 2018 16:05 ET | Source: Fibrocell Science Inc.

Fibrocell Announces Closing of $6.0 Million Registered Direct Offering

EXTON, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 29, 2018 09:20 ET | Source: Fibrocell Science Inc.

Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market

EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 24, 2018 08:56 ET | Source: Fibrocell Science Inc

Fibrocell Announces One-for-Five Reverse Stock Split

EXTON, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 21, 2018 07:00 ET | Source: Fibrocell Science Inc

Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

– FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of...
May 16, 2018 16:05 ET | Source: Fibrocell Science Inc

Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting

EXTON, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...